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The availability of synthetic thyroid hormone receptor ago-
nists provides a valuable tool to analyze whether specific re-
ceptor isoforms mediate specific physiological responses to
thyroid hormone. GC-1 is a thyroid hormone analog display-
ing selectivity for thyroid hormone receptor . We have ana-
lyzed the effect of GC-1 on expression of thyroid hormone
target genes in the cerebrum and cerebellum. Congenitally
hypothyroid rats were treated with single daily doses of either
T3 or GC-1. Both compounds similarly induced Purkinje cell
protein-2 (PCP-2) in the cerebellum. Expression of RC3 and
Rhes in the caudate, and hairless, neurotrophin-3, Reelin, and
Rev-ErbA in the cerebellum, was analyzed by in situ hybrid-
ization on postnatal d 16. Hypothyroidism strongly decreased
expression of RC3 and Rhes in the caudate, and hairless, Rev-
ErbA, and neurotrophin-3 in the cerebellum, and increased
Reelin. T3 treatment normalized the expression of all genes.
However, GC-1 effectively normalized expression of Rhes and
Reelin only. The lack of a GC-1 effect on most cerebellar genes
can be explained by the known distribution of thyroid hor-
mone receptor and isoforms. However, in the caudate, RC3
and Rhes are expressed in the same cells, and therefore, they
may represent specific gene responses linked to specific thy-
roid hormone receptor isoforms. (Endocrinology 144:
5480–5487, 2003)
THE PHYSIOLOGICAL ACTIONS of thyroid hormone(T3) are mediated through interaction with nuclear re-
ceptors, which are ligand-modulated transcription factors
containing hormone and DNA-binding domains (1). There
are several T3 receptor proteins (TRs), encoded by two dis-
tinct genes, TR and TR. The TR gene encodes three pro-
teins, TR1, TR2, and TR3, that differ in their carboxyl
terminus. TR1 binds T3 and activates or represses target
genes, whereas TR2 and TR3 do not bind T3 and may
antagonize T3 action (2, 3). The TR gene also produces two
truncated proteins known as 1 and 2, which have a role
in intestinal development (4). The TR gene produces several
amino-terminal protein variants, TR1, TR2, and TR3, and
the truncated protein TR3 (5), which lacks the DNA-bind-
ing domain and might therefore compete with T3 receptors
for available T3.
The physiological roles and specific functions of the T3
receptor isoforms are being elucidated using two comple-
mentary approaches. One is the use of mutant mice that lack
the expression of single or multiple products of the TR genes
(6, 7). The phenotypes of TR-deficient mice, although not
totally coincident with that of hypothyroid animals, have
allowed relating some discrete specific functions to individ-
ual receptor isoforms. The TR gene is involved in the reg-
ulation of TSH secretion, liver metabolism, and hearing (8, 9),
and the specific product TR2 regulates the development of
a specific subset of photoreceptors involved in color vision
(10); TR1 controls myocardial activity (11) and intestinal
development (12, 13).
A different approach relies on the use of T3 receptor iso-
form-specific agonists. GC-1 is a TR-selective, T3 analog that
has an affinity for TR equal to that of T3 and one order of
magnitude lower affinity for TR1 (14, 15). This compound,
when administered to hypothyroid rats or mice, has similar
effects as T3 on plasma TSH, cholesterol, and triglycerides,
liver malic enzyme, and brown adipose tissue uncoupling
protein-1. These responses may therefore be linked to TR.
In contrast, GC-1 has no effect on heart function and heart
gene expression, which are TR related. In most cases, the
differential effect of GC-1 on physiological endpoints agrees
with the spatial distribution of thyroid hormone receptor
isoforms, supporting the view that the receptor isoforms are
equivalent in their gene targets, and their specific physio-
logical functions depend on their tissue and cell distribution.
However, during adaptive thermogenesis GC-1 was able to
induce brown fat uncoupling protein-1 mRNA as T3 did but
did not potentiate adrenergic responsiveness. These results
suggested that TR and TR are involved in two different
pathways contributing to adaptive thermogenesis (16).
The brain is an important target of thyroid hormone, both
in developing and in adult animals. All receptor isoforms are
expressed in brain, although the TR1 protein accounts for
about 70–80% of total receptor content (17, 18). In some
regions, such as the cerebellum, expression of the TR and
TR genes are segregated into specific cells, but in most
regions both genes are coexpressed although in different
proportions (19, 20). The relative importance of TR vs. TR
may depend on its relative quantitative expression, but,
given the extraordinary cell complexity of the brain, defini-
Abbreviations: BW, Body weight; CAT, chloramphenicol acetyl trans-
ferase; Hr, hairless; NT-3, neurotrophin-3; PCP-2, Purkinje cell-specific
protein-2; TR, T3 receptor protein; TRE, thyroid hormone-responsive
element.
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tion of specific functions of each isoform is a most difficult
task. Recent indications of isoform specificity was provided
recently by us showing that migration of granular cells in the
cerebellum is a TR-dependent response, whereas matura-
tion of Purkinje cells depends on both TR and TR (21).
Also, we found that hippocampal interneurons express dif-
ferentially the TR1 isoform over TR, and adult TR1-
deficient animals have behavioral alterations that may be
related to dysfunction of these interneurons (22). In this work
we have analyzed the effects of GC-1 on expression of a panel
of selected brain genes. We found that GC-1 was without
effect on most genes expressed in the cerebellar granule cell
layer in agreement with the predominant expression of TR
in these cells. However, in the caudate, GC-1 increased the
expression of Rhes, but not RC3, suggesting that different




Rats from the Wistar strain were bred in our animal facilities. Animal
care procedures were conducted in accordance with the guidelines set
by the European Community Council Directives (86/609/EEC). Ani-
mals were under temperature (22 2 C) and light (12-h light, 12-h dark
cycle; lights on at 0700 h) controlled conditions and had free access to
food and water in the colony room. Hypothyroidism was induced by
administering 0.02% 2-mercapto-1-methylimidazole (Sigma Chemical
Co., St. Louis, MO) and 1% sodium perchlorate in the drinking water to
pregnant dams from embryonic d 9 and throughout the experiment.
Hormone treatments consisted of daily single ip injections of 15 ng T3
(Sigma) per gram body weight (BW, which represents five times the total
T3 production rate of about 3 ng/g (23). The TR-selective compound
GC-1 was administered at a dose of 10 ng/g BW. We used the male
neonates from 16 dams, i.e. four litters for each group of control, hy-
pothyroid, and T3- or GC-1-treated hypothyroid pups. Treatments were
started on postnatal d 11 (P11), and the rats were killed 24 h after the last
injection on P16, the time of maximum T3 responsiveness of most brain
target genes. For TSH, T4, and T3 determinations we used two pups from
each litter, i.e. a total of eight pups per condition. For in situ hybridiza-
tion, one rat of each litter, i.e. four rats per condition, was used after
random selection. To check for effects of GC-1 on body growth, an
additional group of animals was treated from P5 through P25. Plasma
TSH levels were measured using immunoreactants kindly supplied by
the Rat Pituitary Agency of the National Institutes of Arthritis, Diabetes,
and Kidney Diseases of the National Institutes of Health (Bethesda, MD),
as previously described (23). Thyroid hormone concentrations were
measured as previously described (23). The TR1/ and wild-type
mice were supplied by Bjo¨rn Vennstro¨m (Karolinska Institute, Stock-
holm, Sweden). For in situ hybridization, four P20 wild-type or TR1/
mice from different litters were processed.
RNA analysis
Northern blotting was performed following standard methods (25)
using 20 g of pituitary total RNA, 50 g of heart total RNA, and 0.5 g
of cerebellum poly (A) RNA. The RNA was isolated from pooled
tissues of 16 pituitaries, four hearts, and eight cerebella for each con-
dition. A 1.6-kb fragment from the 5 end of the sarcoplasmic calcium
adenosine triphosphatase (Serca-2) cDNA (a gift from Dr. W. Dillman,
University of California, San Diego, CA), the full-length cDNA of the GH
gene, and a 440-bp EcoR1-PstI fragment from the cDNA encoding the
Purkinje cell-specific protein (PCP-2) (a gift from Dr. Cary N. Mariash,
University of Minnesota, Minneapolis, MN) were used to prepare the
radioactive probes by the random priming procedure using the Ready-
To-Go DNA Labeling Beads (Amersham Pharmacia Biotech Inc., Pis-
cataway, NJ). As a control for the amount of RNA present in the filters,
blots were hybridized with a glyceraldehyde-3-phosphate dehydroge-
nase probe. The blots were quantitated after autoradiography using
the Scion Image program version 4.02 (Scion Corp., Frederick, MD;
http://www.scioncorp.com).
In situ hybridizations
Animals were perfused transcardially with buffered 4% paraformal-
dehyde, the brains were cryoprotected, and 25-m sagittal sections were
obtained in a cryostat. In situ hybridization with radioactive or digoxi-
genin-labeled riboprobes was performed on floating sections following
procedures previously described in detail (26). Sense and antisense
riboprobes were synthesized from the following cDNA templates as
follows: Rhes, nucleotides 1431–1869; RC3, nucleotides 253–486; Reelin,
nucleotides 1532–3071; neurotrophin-3 (NT-3), nucleotides 1–875; hair-
less (Hr), nucleotides 2703–5186; Rev-ErbA, 600-bp PCR product cor-
responding to exon 1. For quantification, the autoradiographs were
scanned and densitometry was measured with the Scion Image
program.
Transfections and chloramphenicol acetyl transferase
(CAT) assay
Cos-7 cells were grown and maintained in DMEM supplemented
with 10% fetal calf serum. The cells were plated to a density of 250,000
cells/6-cm2 plate the day before transfection. The cells were transfected
by the calcium phosphate protocol (25) using 5 g of the CAT construct,
0.3 g of the expression vector containing the nuclear receptors, and 4
g of the plasmid PCH110, containing the gene for -galactosidase as
an internal control of transfection efficiency. At 16 h after DNA addi-
tions, the medium was changed to medium containing serum that had
been depleted of thyroid hormones by treatment with Dowex resin. T3
or GC-1 was added, and the cells were incubated for 24 h before har-
vesting for determination of -galactosidase and CAT activities.
Data analysis
When data from only two groups were available, Student’s t test was
applied. For multiple comparisons we used one-way ANOVA and the
protected least-significant differences test, after validation of the homo-
geneity of variances by the Levene test. For T4 and T3 concentrations in
liver and neocortex, the analysis was carried out using only the three
hypothyroid groups, treated and untreated. Including the control data
in the set led to nonhomogeneity of variances, which was probably due
to the large differences in values (i.e. one order of magnitude) between
the control and the hypothyroid hormone concentrations. All calcula-
tions were performed with the SPSS statistical package (SPSS Inc., Chi-
cago, IL).
Results
Thyroid hormone concentrations in tissues
Table 1 shows the T4 and T3 concentrations in the neo-
cortex and in liver in control animals (C), untreated hypo-
thyroid animals (H), and T3- or GC-1-treated hypothyroid
animals (H T3 and HGC-1), respectively. The data were
analyzed by ANOVA, and the result of the analysis is shown
in the table footnote. Both T4 and T3 concentrations were
strongly reduced in the hypothyroid animals. In liver, both
T3 and GC-1 treatment still decreased T4 levels further, as a
reflection of TSH suppression. The data show that GC-1 was
as effective as T3 or even more. In T3-treated hypothyroid
rats, T3 was still increased 24 h after the last injection both in
liver and in the neocortex, although residual T3 was higher
in the liver than in the neocortex. This probably reflects the
fact that the entry of T3 into the brain is restricted compared
with the liver. The untreated hypothyroid and GC-1-treated
animals showed the same concentrations of T3, both in liver
and in the neocortex, ensuring that the degree of hypothy-
roidism achieved in the two groups by the antithyroid treat-
Manzano et al. • GC-1 Effects in Brain Endocrinology, December 2003, 144(12):5480–5487 5481
 by on May 19, 2010 endo.endojournals.orgDownloaded from 
ment was similar. For the caudate and cerebellum, we mea-
sured only T3 in untreated hypothyroid and control samples.
The data showed that in the caudate T3 decreased from 1.92
0.37 ng/g in control animals to 0.17  0.01 ng/g in hypo-
thyroid animals (P  0.001), and in the cerebellum from
2.04  0.15 to 0.18  0.03 ng/g (P  0.001).
Effects of GC-1 administration in vivo
We compared the relative effects of GC-1 vs. T3 treatment
given in daily doses to hypothyroid rats on BW, circulating
TSH, and GH and Serca-2 mRNAs in pituitary and heart,
respectively. To assess the effects of T3 and GC-1 on BW (Fig.
1A), these compounds were administered as single daily
injections starting on P5, and the animals were killed at P25.
At the end of the experiment, the BW of untreated hypo-
thyroid rats was 56% of controls. In contrast to T3, which
increased BW to near control levels, GC-1 had no effect.
Circulating TSH and tissue mRNA levels were measured in
P16 rats after treatment with either T3 or GC-1 for 5 d. The
elevated circulating TSH concentrations of hypothyroid an-
imals were normalized by T3 (Fig. 1B). TSH was also reduced
by GC-1, but was less effective than T3, the difference
between the two treatments being statistically significant
(P  0.05).
The responses of selected mRNAs to T3 or GC-1 admin-
istration is shown in Fig. 1C. Pituitary GH mRNA was un-
detectable in hypothyroid rats. Treatment with either T3 or
GC-1 increased mRNA levels, suggesting that thyroid hor-
mone control of pituitary GH is exerted through TR. We
also analyzed the expression of a myocardial gene, the
Serca-2, which is primarily regulated by TR in the heart (27).
The mRNA encoding Serca-2 was decreased in hypothyroid
rats and was increased by T3, whereas the effect of GC-1, if
any, was weak. To ensure that GC-1 was reaching the brain
and eliciting genomic effects, we analyzed the expression of
PCP-2, a gene expressed in Purkinje cells and responsive to
GC-1 administration (21). PCP-2 mRNA was decreased in
hypothyroid rats and was increased by either T3 or GC-1,
with both compounds having similar effects.
Expression of thyroid hormone-dependent genes in
the caudate
We then analyzed the effects of T3 or GC-1 treatment on
the expression of genes known to be under thyroid hormone
regulation in different regions of the brain. For this task we
selected two genes expressed in the caudate, RC3 and Rhes,
and several genes expressed in the cerebellum, namely Hr,
NT-3, Reelin, and Rev-ErbA. The brains were collected after
perfusion of the animals and processed for in situ hybrid-
ization. Figure 2A shows the patterns of expression of RC3
and Rhes in P16 normal, hypothyroid, and hypothyroid rats
treated with either T3 or GC-1. As shown previously, RC3 is
expressed, among other regions, in the caudate nucleus
(CPu) where it is under strong control on adequate supply
of thyroid hormone (28). Rhes is another thyroid hormone-
dependent gene abundantly expressed in the caudate (29). In
agreement with previous data, we found that hypothyroid-
ism resulted in a strongly decreased expression of both genes
in the caudate. Densitometric analysis showed that RC3 de-
creased from 0.35 0.01 (arbitrary units) in control to 0.11
FIG. 1. Effects of T3 or GC-1 on several endpoints of thyroid hormone
action. A, Hypothyroid rats were treated with either T3 (15 ng/g BW)
or GC-1 (10 ng/g BW) starting on P5 until P25, and the weights were
recorded. Shown are the weights of eight control rats (C), eight
hypothyroid rats (H), and eight T3- or GC-1-treated, hypothyroid rats.
B, Serum TSH in P16 control (C) and hypothyroid (H) animals and in
hypothyroid animals treated with either T3 or GC-1 in single daily
doses starting on P11. C, Effects of T3 and GC-1 on pituitary GH, heart
Serca-2, and cerebellar PCP-2 mRNAs. The numbers under the blots
are the ratios of each target gene vs. the control glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) after scanning the blots and den-
sitometry measurements.
TABLE 1. Thyroid hormone concentrations in neocortex and liver
Control rats
Hypothyroid rats (H)
H H  T3 H  GC-1
Neocortex
T4 3.33  0.45 0.31  0.06 0.36  0.08 0.26  0.02
T3 2.35  0.12 0.25  0.12 0.67  0.19
a 0.24  0.05b
Liver
T4 31.56  5.84 1.11  0.18 0.53  0.06
a 0.45  0.08a,b
T3 2.44  0.28 0.23  0.08 1.75  0.18
a 0.20  0.08b
T4 and T3 concentrations were measured in the neocortex and liver of six rats per treatment killed on P16. Results are expressed as nanograms
of T4 or T3 per gram of tissue wet weight (mean  SD). Data from the three hypothyroid groups were subjected to one-way ANOVA, with the
following results: neocortex T4: F2,9  2.47; P  0.14 neocortex T3: F2,9  13.27; P  0.021; liver T4: F2,9  33.7; P  0.0001; liver T3: F2,9 
190.6; P  0.0000. The result of the post hoc analysis is indicated in the table as:
a The differences were significant as compared with the untreated hypothyroid groups; and b the differences were significant comparing the
T3- and GC-1-treated groups.
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0.01 in hypothyroid rats. T3 treatment was able to increase
RC3 expression to near normal levels (0.30 0.02). However,
the effect of GC-1 on RC3 was weak (0.17  0.01). These
results suggested that RC3 was regulated primarily by TR1.
Rhes decreased from 0.60 0.16 in control rats to 0.22 0.03
in hypothyroid animals. Both T3 and GC-1 increased Rhes to
similar levels of 0.40  0.04 and 0.44  0.08, suggesting
TR-mediated induction. Further indication for differential
receptor isoform regulation was provided by examining the
basal expression of RC3 and Rhes in TR1 knockout mice
(Fig. 2B). RC3 expression was decreased in the knockout with
respect to the wild type (0.20 0.01 vs. 0.28 0.02), whereas
Rhes did not change (0.13 0.01 vs. 0.14 0.01). In addition
to a decreased RC3 expression, the normal dorsomedial to
basolateral gradient of expression was also lost in the
TR1/ mice.
The results reported above, suggesting differential regu-
lation of RC3 and Rhes by TR isoforms, were somewhat
unexpected. RC3 and Rhes were previously shown to be
coexpressed in the same cells in the caudate. In this work we
have also confirmed that the two mRNAs are colocalized in
the same cells by performing a combined in situ hybridiza-
tion technique. In agreement with previous data (29), we
found that more than 90% of cells expressing RC3, which
were digoxigenin labeled, were also radioactively labeled by
the Rhes riboprobe. An example of a cell showing both labels
is shown in Fig. 3A. The RC3 gene is regulated at the level
of transcription and contains a thyroid hormone-responsive
element (TRE) located in the first intron (30, 31). Therefore we
checked the possibility that the RC3 TRE was not responsive
to TR. Cos-7 cells were cotransfected with TR or TR,
together with RXR expression vectors and with a CAT re-
porter containing a single copy of the RC3 TRE upstream of
the thymidine kinase promoter (Fig. 3B). CAT activity was
measured after incubating the cells in the absence or presence
of T3 or GC-1 at two different doses, 10
–9 and 10–7 m, in the
presence of 10% serum deprived of thyroid hormones. The
activity of the CAT reporter, which was low in the absence
of any additions, was stimulated by T3 at the two concen-
trations used in the cells transfected with either TR or TR.
The two concentrations of GC-1 were also effective in cells
transfected with TR. However, at the lowest concentration
of 10–9 m, GC-1 had no effect on cells transfected with TR.
Increasing the GC-1 concentration 100-fold elicited a clear
reporter response. These results agree with the lower binding
affinity of GC-1 to TR1 vs. TR. Therefore, the fact that RC3
in the caudate, in contrast to Rhes, was much less responsive
to GC-1 than to T3 was not due to a differential recognition
of the RC3 TRE sequence by the GC-1-TR.
Expression of cerebellar genes
Figure 4 shows representative autoradiographs after in situ
hybridization analysis of selected genes in the cerebellum,
FIG. 2. Differential effects of T3 and GC-1 on thyroid
hormone target genes. Shown are representative in
situ hybridization autoradiographs and to the right-
hand side of the figures the quantification of the
respective autoradiograph signal. A, RC3 and Rhes
expression by in situ hybridization on coronal brain
slices of P16 control (C), hypothyroid (H), and hypo-
thyroid rats treated with T3 or GC-1 starting on P11.
RC3 was responsive to T3 but not GC-1 in the caudate
(CPu), whereas Rhes was responsive to both com-
pounds. The data were analyzed by ANOVA, after
confirming homogeneity of variances, with the fol-
lowing result: RC3, F3,12  397.7, P  0.0000; Rhes,
F3,8  15.1, P  0.001. An asterisk between bars
indicates statistically significant differences after
the least-significant differences post hoc test. B, RC3
and Rhes expression in the caudate of wild-type (wt)
and TR1/ (ko) mice. The data were analyzed by
using the Student’s t test for single comparisons. ***,
P  0.001; ns, nonsignificant. Scale bar, 1.4 mm.
FIG. 3. A, Coexpression of RC3 and Rhes in the same cell. Shown is
a cell of the caudate after a combined in situ hybridization using a
digoxigenin-labeled riboprobe for RC3 and a radioactive probe for
Rhes. Scale bar, 30 m. B, Transactivation assays in Cos-7 cells using
the RC3 TRE upstream of the thymidine kinase promoter driving
expression of the CAT gene. The cells were cotransfected with the
reporter plasmid and expression vectors encoding TR1 or TR1 and
treated with either T3 or GC-1 in the presence of thyroid hormone-
deprived serum.
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and the quantification of results is shown in Fig. 5. Hr was
prominently expressed in the internal granular layer of nor-
mal animals and was strongly decreased in hypothyroid
animals, confirming previous results by other investigators
(32, 33). T3 treatment, but not GC-1, was effective in increas-
ing mRNA levels to normal. NT-3 is also regulated by thyroid
hormone during brain development (34). NT-3 expression
also occurred in the internal granular layer but was not
homogeneous throughout the slice. Expression was stronger
in posterior lobules VII, VIII, and IX. Hypothyroidism af-
fected more strongly lobules I–VI and X. T3 treatment nor-
malized NT-3 expression, whereas GC-1 was without effect.
Reelin was shown to be negatively regulated by thyroid
hormone in the cerebellum (35). Accordingly, Reelin mRNA
was increased in hypothyroidism, especially in central and
posterior lobules, and decreased after T3 treatment. At this
stage of development, migration of granular cells was not
complete, and Reelin mRNA was also present in the external
germinal layer. GC-1 was as effective as T3 in decreasing
Reelin expression after administration to hypothyroid ani-
mals. Finally, we found that Rev-ErbA is also thyroid hor-
mone dependent in the cerebellum, a fact that was not known
so far. It was strongly reduced by hypothyroidism in the
granular cells, leaving a residual signal arranged in a row-
like fashion possibly due to expression in either the Purkinje
or the basket cells. T3 treatment increased Rev-ErbA ex-
pression in the granular cells, but GC-1 was without effect.
Discussion
Previous studies showed that GC-1 is effective at reducing
TSH and elevated cholesterol levels in hypercholesterolemic
rats, and cholesterol levels in hypothyroid mice (27), but has
no significant effect on heart rate in either case. TSH and
cholesterol are primarily TR-mediated responses, whereas
heart rate is mediated by TR1 (11). In our hands, GC-1
administration to hypothyroid rats reduced plasma TSH,
although, in agreement with other studies (15), was less
effective than an equivalent dose of T3. This might be due to
the fact that pituitary TSH is under control of both TR and
TR1 (36). Also, as previously reported, GC-1 has no effect
on body weight, despite the fact that it increased the expres-
sion of pituitary GH in a similar way as T3. The increased
pituitary GH after GC-1 treatment suggests that GH is under
control of TR. It has been proposed that GH is regulated
specifically by TR2 (37) although TR/ or TR2/ mice
have normal GH mRNA levels. In fact, in TR-deficient
mice a decreased GH expression can only be achieved in
TR/TR/mice, suggesting redundancy among TRs. In
hypothyroid animals the situation is different from that of
FIG. 4. Expression of cerebellar genes and the effects of T3 and GC-1. Shown are sagittal slices of cerebellum (anterior lobes are to the left,
posterior lobes to the right) after in situ hybridization and autoradiography of P16 control (C), hypothyroid (H), and hypothyroid rats treated
with T3 (H  T3) or GC-1 (H  GC-1). Lobule numbering is indicated in the control section for Hr. Scale bar, 2.3 mm.
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receptor-deficient animals, because the unliganded receptors
may repress the target genes. Therefore the suppressed GH
gene expression in hypothyroid animals might be due to the
repressor activity of unliganded receptors. From our results
it appears that liganded TR is sufficient to normalize GH
expression. In the myocardium, Serca-2 mRNA, primarily a
TR1 response (27), was decreased in hypothyroid rats and
increased by T3 but not by GC-1. Therefore our control ex-
periments indicated that at the doses used, GC-1 was acting
primarily, if not exclusively, through TR1.
There are very few data on GC-1 effects on brain. In this
work we have analyzed the effect of GC-1 on gene expression
of selected genes in the cerebrum and in the cerebellum. In
agreement with previous work (21), GC-1 was effective in
inducing PCP-2 mRNA in the cerebellum. GC-1 is therefore
able to enter the brain and effect genomic actions. Cerebellar
PCP-2 is specifically transcribed in the Purkinje cells, which
express primarily TR1, so that the PCP-2 response to thy-
roid hormone is presumably mediated by TR1. To gain
more insight into the roles of TR and TR in the brain, we
selected RC3 and Rhes because they are coexpressed in the
caudate, where they show a strong dependence on thyroid
hormone. RC3 is a protein kinase C substrate involved in
Ca2 and glutamate receptor signaling at the postsynaptic
terminal (38). It is regulated by thyroid hormone at the level
of transcription, presumably through a TRE located in the
first intron. Rhes is a novel Ras-related protein greatly en-
riched in the striatum (39), also induced by thyroid hormone
by a mechanism that remains unknown. Surprisingly, Rhes
was responsive to T3 and GC-1, whereas RC3 was induced
by T3, with GC-1 having little effect. The reasons for the weak
induction of RC3 by GC-1 are at present unknown. RC3 and
Rhes are coexpressed in the main cells of the caudate, the
medium-sized, spiny, -aminobutyric acid (GABA)ergic
cells. These cells express both TR and TR, as shown by
colocalization analysis with RC3 (40). Therefore, GC-1
should have elicited the same effect on RC3 as on Rhes. The
possibility that the sequence of the RC3 TRE was not rec-
ognized by the GC-1-activated TR was discarded by trans-
activation analysis that showed that TR was able to induce
FIG. 5. Quantification of the autoradiograph data
of Fig. 4. The figure shows the mean  SD of den-
sitometric analysis performed on the autoradio-
graphs after in situ hybridization of cerebellar
genes. Four slices for each gene from different pups
were used for measurements. The data for Hr and
Rev-ErbA were taken from lobule VIII and for
NT-3 and Reelin from lobules I and VIII. The data
were analyzed by ANOVA with the following re-
sults: Hr, F3,12  387.5, P  0.0000; Rev-ErbA,
F3,12  899.2, P  0.0000; NT-3, lobule I, F3,12 
4338.3, P 0.0000; NT-3, lobule VIII, F3,12 40.0,
P  0.0000; Reelin, lobule I, F3,12  30.2, P 
0.0000; Reelin, lobule VIII, F3,12  422.2, P 
0.0000. Statistically significant differences be-
tween groups are shown by asterisks.
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the activity of a reporter gene after GC-1 addition to the cells.
A preliminary conclusion of these experiments is that RC3
and Rhes represent thyroid hormone responses elicited
through specific receptor isoforms in the same cell. One can
speculate that in the environment of the RC3 intronic TRE,
TR1 might interact more productively than TR with the
transcriptional machinery. The role of TR1 in regulation of
RC3, but not Rhes, agreed with data from TR1/ mice
showing that RC3, but not Rhes, was significantly decreased
in the absence of TR1.
The effects of T3 and GC-1 on genes expressed in the
granular cells of the cerebellum suggest that regulation of
these genes is exerted primarily through TR1. This is in
agreement with the fact that granular cells express predom-
inantly TR1 (19, 20). In a previous work we have shown that
GC-1 did not induce granular cell migration, despite partially
correcting the arrested Purkinje cell differentiation caused by
early postnatal hypothyroidism (21). An exception to this
pattern of regulation was Reelin, which was down-regulated
by GC-1 in a similar manner as by T3, despite granule cell
expression. Thyroid hormone positively regulates Reelin in
the cerebral cortex, whereas in the cerebellum, the pattern of
regulation is complex, switching from a positive to a negative
regulation as development proceeds (35). This complex pat-
tern of regulation suggests that other influences, for example
Purkinje cell-derived brain-derived neurotrophic factor, and
possibly other factors, are involved in Reelin regulation.
Therefore, the effects of GC-1 on Reelin expression by gran-
ule cells may be an indirect consequence of an effect on the
Purkinje cells.
Among the cerebellar genes studied we show that Rev-
ErbA is under thyroid hormone regulation, a fact that was
previously unknown. Rev-ErbA plays an important role
during cerebellar development. During the first week after
birth it is expressed in the Purkinje cells, and as development
proceeds, its expression increases in the internal granular
layer and basket cells and decreases in the Purkinje cells (41).
Accordingly, we found that at P16 most Rev-ErbA signal
was present in the internal granular layer where it is under
strong regulation by thyroid hormone. We believe that our
findings are important because deletion of this gene in mice
induces a cerebellar phenotype similar to that of hypothy-
roidism, i.e. stunted growth of Purkinje cells and delayed
migration of granule cells (41). Therefore regulation of Rev-
ErbA expression might be at least partly responsible for the
effects of thyroid hormones on cerebellar development.
A point of concern has been the availability of GC-1 to the
brain after in vivo administration. A full pharmacokinetic
analysis of GC-1 has not been carried out, but a preliminary
study to measure plasma levels and tissue distribution from
a single dose has been reported (27). These results indicate
that GC-1 has a substantially shorter serum half-life than T3,
but the efficiency of absorption into most tissues is not dra-
matically different from that of T3. In brain, which is the
relevant tissue for this paper, T3 has a tissue/plasma ratio of
0.56, whereas the ratio for GC-1 is 0.13, indicating that GC-1
absorbs into the brain from plasma four times less efficiently
than T3. For comparison, the same analysis on the liver, in
which GC-1 displays potent lipid-lowering activity, shows
that GC-1 is absorbed about three times less efficiently than
T3. The results described in this paper demonstrate that GC-1
administration in vivo, at the doses used, is as effective as T3
in cells containing primarily TR1 as Purkinje cells, whereas
it has no effect on cells containing primarily TR1 as cere-
bellar granule cells.
In conclusion, the TR-specific T3 analog GC-1 is able to
induce typical gene responses to thyroid hormone in the
brain, and the patterns of regulation agree with the known
distribution of thyroid hormone receptor isoforms in the
cerebellum. In the caudate, however, where TR and TR are
expressed in the same cells, the lack of effect of GC-1 on RC3
suggests that this gene is specifically regulated by TR. The
data further suggest that regulation by thyroid hormone
receptor isoforms follows two types of specificity: one, which
is due to specific cell type expression of receptor isoforms,
and an additional one, which is due to specific gene recog-
nition by individual isoforms.
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